In Case You Missed It
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
You have to keep up with the sector rotations.
Icahn may have a tough time finding interest in this behemoth.
These two large-cap drug giants should be core parts of any well-diversified portfolio.
The company discusses potential share repurchases and its acquisition strategy.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.